Evidence map›Paper›PMID 35748017›Full record

ArticleThe Journal of international medical research2022

Warfarin resistance: possibilities to solve this problem. A case report.

Halyna Mostbauer, Olga Nishkumay, Oksana Rokyta, Valeriia Vavryniuk

Open access · goldAbstract readCase Reports
In one paragraph

Article in The Journal of international medical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. From warfarin resistance to warfarin overdose: an unusual case report.Drug metabolism and personalized therapy · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Halyna MostbauerDepartment of Internal Medicine Number 2, Bogomolets National Medical University, Kyiv, Ukraine.
Olga NishkumayDepartment of Internal Medicine Number 2, Bogomolets National Medical University, Kyiv, Ukraine.
Oksana RokytaDepartment of Internal Medicine Number 2, Bogomolets National Medical University, Kyiv, Ukraine.ORCID https://orcid.org/0000-0002-7248-2817
Valeriia VavryniukDepartment of Internal Medicine Number 2, Bogomolets National Medical University, Kyiv, Ukraine.
Bogomolets National Medical University · UA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Effective prevention of thromboembolism is essential for patients with mechanical prosthetic heart valves. For this group of patients, vitamin K antagonists (VKAs) remain the drug group of choice despite the widespread use of new anticoagulants in other diseases. As a consequence, warfarin resistance remains a serious challenge for physicians. The current report describes a 65-year-old male patient that had a mechanical prosthetic aortic valve implanted due to severe aortic insufficiency after infective endocarditis. Despite consistent increases in his warfarin dose, the level of international normalized ratio (INR) remained very low. The patient was considered to have warfarin resistance. Warfarin was successfully replaced by another VKA, acenocoumarol, which resulted in a stable INR observed over 1 year of follow-up. Achieving the target INR in patients with mechanical prosthetic heart valves using VKAs is the main goal of thromboprophylaxis. Although the genetic changes that cause warfarin resistance are understood, the options to overcome these pharmacogenetic issues remain limited. Based on the success with this current patient, physicians with similar patients with warfarin resistance might wish to consider replacing warfarin with acenocoumarol.

Indexed as

Heart Valve ProsthesisVenous ThromboembolismAcenocoumarolAgedAnticoagulantsFibrinolytic AgentsHumansInternational Normalized RatioMaleMetabolism, Inborn ErrorsWarfarinAcenocoumarolAnticoagulantsFibrinolytic AgentsWarfarinacenocoumarolPrevention of prosthetic valve thrombosiswarfarin resistance

Identifiers

PMID35748017
PMCPMC9235305
OpenAlexW4283397151

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.